Stock RPTX REPARE THERAPEUTICS INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Repare Therapeutics Inc.

Equities

RPTX

US7602731025

Market Closed - Nasdaq
Other stock markets
 16:00:00 2024-04-29 EDT 		5-day change 1st Jan Change
3.2 USD 0.00% Intraday chart for Repare Therapeutics Inc. -1.84% -56.16%
04-26 Repare Therapeutics Inc. Announces Directorate Changes CI
02-28 Repare Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Repare Therapeutics Appoints Steven H. Stein, M.D. to its Board of Directors
BU
Repare Therapeutics Inc. (RPTX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
BU
Repare Therapeutics Inc. (RPTX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
BU
Pomerantz Law Firm Investigates Claims on Behalf of Investors of Repare Therapeutics Inc. - RPTX
PR
Pomerantz Law Firm Investigates Claims on Behalf of Investors of Repare Therapeutics Inc. - RPTX
PR
Repare Therapeutics to Participate in Two Upcoming Investor Conferences
BU
Repare Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
BU
Pomerantz Law Firm Investigates Claims on Behalf of Investors of Repare Therapeutics Inc. - RPTX
PR
Kirby McInerney LLP Announces Investigation of Shareholder Claims Against Repare Therapeutics Inc. (RPTX)
BU
Pomerantz Law Firm Investigates Claims on Behalf of Investors of Repare Therapeutics Inc. - RPTX
PR
Repare Therapeutics Doses First Patient in Phase 1 Clinical Trial of RP-1664
BU
Repare Therapeutics to Regain Global Rights to Camonsertib
BU
Repare Therapeutics Announces Achievement of $40 Million Roche Clinical Milestone Payment
BU
Repare Therapeutics Provides Corporate Update and Highlights Anticipated Key 2024 Milestones
BU
Repare Therapeutics and Debiopharm Partner to Explore the Synthetic Lethal Combination of PKMYT1 and WEE1 Inhibition in Cancer
BU
Repare Therapeutics Insiders Establish Automatic Securities Disposition Plans
BU
Repare Therapeutics Unveils Two Programs Expected to Enter Clinical Trials in 2024, RP-1664, an Oral PLK4 Inhibitor, and RP-3467, an Oral Pol Inhibitor
AQ
Repare Therapeutics Unveils Two Programs Expected to Enter Clinical Trials in 2024: RP-1664, an Oral PLK4 Inhibitor, and RP-3467, an Oral Polθ Inhibitor
BU
Repare Therapeutics Provides Business Update and Reports Third Quarter 2023 Financial Results
BU
VedaBio Unveils World Class Scientific Advisory Board
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. RPTX Stock
  4. News Repare Therapeutics Inc.
  5. Press Releases